Left Atrial Appendage Closure With the LAmbre

Exclusion Criteria

• •1. Presence of rheumatic, degenerative or congenital valvular heart diseases,
• •2. The diameter of left atrial ≥65 mm;
• •3. LAA size \< 12mm or \> 30 mm
• •4. Left atrium has been removed;
• •5. Heart transplantation patients;
• •6. Symptomatic patients with carotid artery disease (such as carotid stenosis ≥ 50%);
• •7. Acute myocardial infarction or unstable angina;
• •8. Decompensated heart failure (New York Heart Association functional class III-IV);
• •9. Recent myocardial infarction (\< 3 months);
• •10. Patients with an atrial septal defect or received an atrial septal occluder. The patient has an ablation procedure planned within 30 days of potential LAmbre Occluder implant
• •11. The patient has a planned cardioversion 30 days post implant of the LAmbre Occluder
• •12. Patient who after artificial mechanical heart valve replacement operation;
• •13. Uncontrolled Heart rate ≥ 110 beats / min17) History stroke or TIA within 30 days;
• •14. Presence of complex aortic plaque(4mm) in ascending aorta;
• •15. Cardiac tumors or other malignancy with estimated life expectancy u less than 2 years;
• •16. Have thrombocytopenia (platelet 《105 / μl) or anemia（Hb\<10g/dl）;
• •17. Women who is pregnancy or plan to pregnancy during the trial period;
• •18. Presence of active sepsis or endocarditis;
• •19. Patient participated in the other trials;
• •20. The investigators expect the patient not be able to complete the trial according to requirements.
• •1. LVEF≤30%;
• •2. Presence of left atrial appendage thrombus;
• •3. High risk PFO patients(presence of atrial septal aneurysm);
• •4. Have obvious mitral valve stenosis (the area of mitral valve≤ 2 cm2);
• •5. Have obvious and unexplained pericardial effusion(≥4 cm2).
• •6. Presence of complex aortic plague(≥4 mm) in ascending aorta.